J&J’s Carvykti and BMS’ Abecma Win FDA Approvals for Earlier Use in Multiple Myeloma
XTalks
APRIL 11, 2024
While the language is similar to those on other CAR T-cell therapies, Abecma’s warning has a slight distinction as it describes cases of secondary cancers linked to the treatment of hematologic malignancies specifically. This could be seen as a positive for companies developing CAR T-cell therapies for autoimmune diseases and solid tumors.
52 
Let's personalize your content